Meeting
2024 ASCO Annual Meeting
Neoadjuvant adebrelimab plus dalpiciclib in HPV-negative locally advanced head and neck squamous cell carcinoma: A phase II clinical trial.
Authors
Lei Liu
Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
Lei Liu , Yi Li , Fei Chen , Chunjie Li , Huixu Xie , Zhuoyuan Zhang , Xiang Xz , Yuanyuan Zeng , Jun Wang , Bowen Zhang , Chenfeng Tan , Zelei Dai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT06199271
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS6129)
DOI
10.1200/JCO.2024.42.16_suppl.TPS6129
Abstract #
TPS6129
Poster Bd #
437a
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
First Author: yueyun chen
Poster
2023 ASCO Annual Meeting
A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck.
First Author: Di Wu
Poster
2023 ASCO Annual Meeting
Induction therapy of toripalimab combined with docetaxel and cisplatin in locally advanced hypopharyngeal squamous cell carcinoma (HPSCC): A single-arm, phase II clinical trial.
First Author: Chunmei Bai
Poster
2023 ASCO Annual Meeting
Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01).
First Author: Min Yan